Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 4—April 2026

Research

Evaluation of Effectiveness of Autocidal Gravid Ovitraps for Preventing Zika Virus Infection, Puerto Rico, USA

Zachary J. MadewellComments to Author , Sandra J. Kiplagat, India Kellum, Matthew J. Lozier, Olga Lorenzi, Janice Perez-Padilla, Freddy A. Medina, Jorge L. Muñoz-Jordán, Laura E. Adams, Gabriela Paz-Bailey, Stephen H. Waterman, Roberto Barrera, and Tyler M. Sharp
Author affiliation: Centers for Disease Control and Prevention, San Juan, Puerto Rico, USA (Z.J. Madewell, S.J. Kiplagat, I. Kellum, M.J. Lozier, O. Lorenzi, J. Perez-Padilla, F.A. Medina, J.-L. Muñoz-Jordán, L.E. Adams, G. Paz-Bailey, S.H. Waterman, R. Barrera, T.M. Sharp); US Public Health Service Commissioned Corps, Rockville, Maryland, USA (L.E. Adams, T.M. Sharp)

Main Article

Table 2

Reported acute febrile illness and symptom profiles among participants in an evaluation of effectiveness of autocidal gravid ovitraps for preventing Zika virus infection, Puerto Rico, USA *

Characteristics Overall, n = 270† ZIKV-positive, n = 40 ZIKV-negative, n = 230 p value‡
Acute febrile illness 58 (21.5) 15 (37.5) 43 (18.7) 0.014
Rash 31 (11.5) 11 (27.5) 20 (8.7) 0.002
Fever 47 (17.4) 12 (30.0) 35 (15.2) 0.040
Joint pain 51 (18.9) 13 (32.5) 38 (16.5) 0.030
Sought medical care for illness 36 (13.3) 8 (20.0) 28 (12.2) 0.275
Hospitalized for illness 2 (0.7) 1 (2.5) 1 (0.4) 0.684

*Values are no. (%). ZIKV, Zika virus. †One ZIKV-negative participant with missing information on acute febrile illness and related symptom history was excluded from this table. ‡χ2 test was used for comparison of percentages and Fisher exact test was for comparison of categories with >1 value <5.

Main Article

Page created: March 04, 2026
Page updated: April 01, 2026
Page reviewed: April 01, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external